Langer, Ciechanover god­fa­ther the lat­est AI up­start; Ipsen forges $446M AML de­vel­op­ment pact

There’s a new AI play­er jump­ing in­to the drug dis­cov­ery game. And they have some high-pow­ered sci­en­tif­ic ad­vi­sors in their cor­ner.

Tel Aviv-based Quris has built what it calls a “pa­tient-on-a-chip” AI plat­form that it’s tout­ing as a way to cir­cum­vent un­re­li­able an­i­mal test­ing with a more ef­fi­cient way to judge safe­ty and ef­fi­ca­cy. An­i­mal test­ing, par­tic­u­lar­ly in­volv­ing mice, has proven a no­to­ri­ous­ly un­re­li­able way to do pre­clin­i­cal test­ing — though it is well-es­tab­lished with reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER